ARTICLE | Distillery Therapeutics
Cancer
August 29, 2017 6:09 PM UTC
Mouse studies suggesting inhibiting LOXL2 could help treat metastatic breast cancer. In a mouse model of breast cancer, mammary gland-specific knockout of LOXL2 decreased lung metastatic burden and the number circulating tumor cells (CTCs) compared with normal LOXL2 expression. Next steps could include testing LOXL2 inhibitors in models of metastatic breast cancer.
PharmAkea Therapeutics Inc. has the LOXL2 inhibitor PAT-1251 in Phase I testing to treat pulmonary fibrosis...
BCIQ Company Profiles
BCIQ Target Profiles